No Data
West Point Pharmaceutical (301130.SZ): Some fundraising projects are proposed to be postponed.
On January 20, Gelonghui announced that Xidian Pharmaceutical (301130.SZ) held the 10th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on January 20, 2025, during which the proposal to postpone some fundraising investment projects was reviewed and approved. It was agreed that under the premise that the main body of the fundraising investment project, implementation methods, construction content, purpose of raised funds, and investment scale remain unchanged, the scheduled usable status time for the 'Traditional Chinese Medicine Modern Extraction Workshop Construction Project' would be extended to May 23, 2025, and the scheduled usable status for the 'Escitalopram Oxalate Active Pharmaceutical Ingredient Production Project' would also be similarly adjusted.
The main shareholder of West Point Pharmaceuticals (301130.SZ), Hengqin Dingdian and its concerted parties, completed a Shareholding of 0.7574 million shares.
Xidian Pharmaceutical (301130.SZ) announced that the Shareholder holding more than 5% of the shares, Hengqin Dingdian Private Equity Fund Partnership...
West Point Pharmaceutical (301130.SZ): The domestic production supplementary application for Levofloxacin eye drops has been accepted.
West Point Pharmaceutical (301130.SZ) issued a notice that the company recently received a signed document from the National Medical Products Administration regarding Leflufen.
West Point Pharmaceutical (301130.SZ): The company currently has Traditional Chinese Medicine products such as Xin Nao Kang capsules and Jiang Tang Ning capsules.
On January 9, Gelonghui reported that Western Point Pharmaceutical (301130.SZ) disclosed the record of investor relations activities, indicating that Traditional Chinese Medicine products are an important aspect of the company's Global Strategy layout. The company currently has Traditional Chinese Medicine products such as Xinnaokang capsules, Jiangtangning capsules, Yigan Fuzheng capsules, Yigan Jiedu capsules, and Sanqi tablets. The company is actively venturing into the big health product field through its wholly-owned subsidiary, Western Point (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., reviewing existing reserve projects and accelerating the progress of projects that align with the company's Global Strategy.
Shareholder Hengqin Dingdian and its concerted actors have cumulatively reduced their shareholding by 1.5358 million shares.
Western Point Pharmaceutical (301130.SZ) announced that the company's Shareholder Hengqin Dingdian and its concerted action party Zhuhai Hengqin Runhui Yi...
A-share midday announcement: Xiaoming Co.'s chicken product sales revenue in November increased by 7.36% month-on-month.
1. Xiaoming Co., Ltd.: In November 2024, the company sold 24.1197 million chicken products, achieving sales revenue of 92.8349 million yuan, with quarter-on-quarter growth of 2.71% and 7.36%, and year-on-year growth of 26.43% and 98.04% respectively. 2. Xidian Pharmaceutical: The oral solution of levofloxacin was granted approval notification for a pharmaceutical supplementary application, changing the marketing authorization holder from "shandong longnuo pharmaceutical Co., Ltd." to "jilin province xidian pharmaceutical technology development Co., Ltd.".
Does The Market Have A Low Tolerance For Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd's (SZSE:301130) Mixed Fundamentals?
